Moody Aldrich Partners LLC cut its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) by 43.3% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 106,798 shares of the company's stock after selling 81,523 shares during the quarter. Moody Aldrich Partners LLC owned 0.38% of TransMedics Group worth $3,359,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Swiss National Bank raised its holdings in TransMedics Group by 7.7% during the first quarter. Swiss National Bank now owns 59,100 shares of the company's stock worth $1,592,000 after purchasing an additional 4,200 shares during the last quarter. Divisadero Street Capital Management LP purchased a new position in TransMedics Group during the first quarter worth $323,000. Signature Wealth Management Partners LLC purchased a new position in TransMedics Group during the first quarter worth $329,000. Oppenheimer & Co. Inc. purchased a new position in TransMedics Group during the first quarter worth $257,000. Finally, Boston Partners increased its position in TransMedics Group by 13.6% during the first quarter. Boston Partners now owns 18,811 shares of the company's stock worth $507,000 after buying an additional 2,251 shares in the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.
Get TransMedics Group alerts:Analysts Set New Price Targets
TMDX has been the subject of several recent research reports. Cowen raised their price target on TransMedics Group from $45.00 to $50.00 in a research report on Tuesday, August 2nd. JPMorgan Chase & Co. raised TransMedics Group from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $26.00 to $48.00 in a research report on Tuesday, August 2nd. Cowen raised their price target on TransMedics Group from $39.00 to $45.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 26th. Oppenheimer raised their price target on TransMedics Group from $40.00 to $45.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 2nd. Finally, Morgan Stanley lifted their price objective on TransMedics Group from $34.00 to $37.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 3rd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $46.00.
Insider Buying and Selling at TransMedics Group
In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,929 shares of the business's stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $46.74, for a total transaction of $604,301.46. Following the completion of the sale, the chief executive officer now owns 493,285 shares of the company's stock, valued at $23,056,140.90. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,929 shares of the business's stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $46.74, for a total transaction of $604,301.46. Following the transaction, the chief executive officer now owns 493,285 shares in the company, valued at $23,056,140.90. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Waleed H. Hassanein sold 2,277 shares of the business's stock in a transaction dated Wednesday, September 7th. The stock was sold at an average price of $55.00, for a total value of $125,235.00. Following the transaction, the chief executive officer now owns 464,008 shares in the company, valued at approximately $25,520,440. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 180,949 shares of company stock valued at $7,144,651. Company insiders own 8.70% of the company's stock.TransMedics Group Trading Down 2.7 %
Shares of NASDAQ:TMDX opened at $41.68 on Friday. The company has a quick ratio of 3.41, a current ratio of 4.18 and a debt-to-equity ratio of 0.70. TransMedics Group, Inc. has a 52 week low of $10.00 and a 52 week high of $56.41. The business has a fifty day simple moving average of $45.92 and a 200-day simple moving average of $33.42.
TransMedics Group (NASDAQ:TMDX – Get Rating) last posted its quarterly earnings results on Monday, August 1st. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.09). TransMedics Group had a negative net margin of 92.76% and a negative return on equity of 74.20%. The firm had revenue of $20.52 million for the quarter, compared to analysts' expectations of $16.26 million. During the same period last year, the firm posted ($0.39) EPS. On average, sell-side analysts predict that TransMedics Group, Inc. will post -1.57 EPS for the current year.
TransMedics Group Company Profile
(Get Rating)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Articles
- Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.